Company Overview

Frontage Holdings Corporation is a global contract research organization (CRO) that provides integrated research and development services to pharmaceutical, biotechnology, and medical device companies. The company operates across the drug discovery, preclinical, clinical, and post-marketing stages, supporting clients in advancing therapeutics from early research through regulatory approval. Its services are used by both multinational pharmaceutical companies and emerging biotech firms seeking outsourced R&D capabilities.

The company’s primary revenue drivers include drug discovery and preclinical services, clinical trial services, and laboratory testing and bioanalytical services. Frontage positions itself as a cross-border CRO with a strong U.S. operational base and growing China presence, enabling it to serve clients conducting global development programs. Frontage was founded in 2007 and has expanded primarily through organic growth and targeted acquisitions, culminating in its public listing in Hong Kong in 2018. Its ordinary shares also trade in the U.S. OTC market under the ticker FGHQF.

Business Operations

Frontage operates through multiple integrated business lines that collectively cover a broad portion of the pharmaceutical R&D value chain. Its core segments include Drug Discovery Services, Preclinical Services, Clinical Services, and Laboratory Services, which generate revenue primarily through fee-for-service contracts. These services encompass medicinal chemistry, biology, pharmacology, toxicology, clinical trial management, data management, and bioanalytical testing.

Operations are conducted through a network of wholly owned subsidiaries, including Frontage Laboratories, Inc., which serves as the principal U.S. operating entity. The company maintains laboratories, research facilities, and clinical service teams that support both domestic and international projects. Frontage relies on proprietary platforms, validated laboratory technologies, and regulatory-compliant systems aligned with U.S. FDA and international standards, forming a key part of its service differentiation.

Strategic Position & Investments

Frontage’s strategic direction emphasizes expanding its end-to-end CRO capabilities while strengthening its position in high-growth therapeutic areas such as oncology, metabolic diseases, and central nervous system disorders. Growth initiatives have included capacity expansion in laboratory infrastructure, enhancement of clinical trial execution capabilities, and continued investment in integrated service offerings that reduce development timelines for clients.

The company has pursued selective acquisitions to broaden its service scope and geographic reach, including the acquisition of Bridger Bioanalytics, Inc., which enhanced its bioanalytical and biomarker capabilities. Frontage also continues to invest in advanced analytical technologies and digital clinical trial tools to improve data quality and operational efficiency, aligning with industry trends toward decentralized and technology-enabled trials.

Geographic Footprint

Frontage operates primarily across North America and Asia, with its global headquarters located in Exton, Pennsylvania, United States. The U.S. represents its largest revenue-generating region, supported by multiple laboratory and research facilities that service both domestic and international clients.

In China, Frontage maintains a growing operational presence through subsidiaries and research centers that support discovery, preclinical, and clinical services for local and multinational customers. The company’s cross-border operating model allows it to facilitate regulatory-compliant development programs spanning the U.S., China, and other international markets, giving it influence across key global pharmaceutical development corridors.

Leadership & Governance

Frontage was founded by Dr. Song Li, who has played a central role in shaping its scientific and operational strategy. The leadership team emphasizes regulatory compliance, scientific rigor, and integrated service delivery as core elements of the company’s governance and growth philosophy.

Key executives include:

• Song Li – Founder, Chairman of the Board, and Chief Executive Officer
• Jiangping Zhang – Chief Financial Officer
• Xiaohui Zhang – Chief Operating Officer
• Yi Zhang – Chief Scientific Officer

The board and management team collectively bring experience in pharmaceutical R&D, regulatory science, and global CRO operations, supporting Frontage’s long-term strategy of sustainable international expansion and service integration.